Skip to main content
Premium Trial:

Request an Annual Quote

Michael Gutch

Premium
Michael Gutch has joined the life sciences investment group at Miami-based HIG Ventures, the venture capital affiliate of HIG Capital.
 
Prior to joining HIG, Gutch was a principal with Lilly Ventures, the corporate venture capital group of Eli Lilly, where he focused on early-stage investments in biopharmaceutical companies. During this time, he also previously served as a board director for Protagonist Therapeutics and board observer for Hydra Biosciences and Calistoga Pharmaceuticals.
 
Prior to his time with Eli Lilly, Gutch was employed by Genentech and Spring Mill Venture Partners. He holds a PhD in cellular and molecular pathology from the State University of New York, and conducted his postdoc at the University of California, San Francisco, and Cold Spring Harbor Laboratory.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.